Actinogen extends cash runway as pivotal Alzheimer’s trial advances

Actinogen Medical ( (AU:ACW) ) has shared an announcement.

Actinogen Medical reported progress on its pivotal XanaMIA phase 2b/3 Alzheimer’s trial, with an independent Data Monitoring Committee recommending the study continue unchanged after a positive interim analysis of safety and futility. The 247‑patient trial, intended as one of two pivotal studies to support marketing approval for Xanamem, completed enrolment in late 2025, with topline results expected in November 2026 and planning under way for a larger second pivotal trial.

The company also launched an open‑label extension to provide long‑term access to Xanamem for up to 25 months, achieving an 88% rollover of recent trial completers and generating extended safety and observational efficacy data to support future regulatory filings. Funding was bolstered by a $16.8 million capital raising, $7.3 million in FY2025 R&D tax incentives and a $4.3 million non‑dilutive facility, leaving $21.5 million in cash and a runway beyond the XanaMIA readout, while commercial, regulatory and market‑readiness activities continued in anticipation of potential approval pathways.

The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical is an Australian clinical‑stage biotechnology company focused on developing Xanamem, a small‑molecule therapy for Alzheimer’s disease and related neurological conditions. The company is targeting the growing market for disease‑modifying and symptomatic treatments in dementia, aiming to position Xanamem as a pivotal candidate in Alzheimer’s care.

Average Trading Volume: 3,459,506

Technical Sentiment Signal: Hold

Current Market Cap: A$158M

See more insights into ACW stock on TipRanks’ Stock Analysis page.